Five-Year Real-World Hard Outcomes of Vedolizumab in Inflammatory Bowel Disease: The IG-IBD LONG-LIVE Study.

Privitera G, Palumbo F, Macaluso FS, Laterza L, Pardi V, Viola A, Noviello D, Barberio B, Ricci C, Balestrieri P, Cappello M, Maconi G, Sablich R, Variola A, Bennato R, Pastorelli L, Grossi L, Ribaldone DG, Buda A, Bossa F, Di Sario A, Viscido A, Neri B, Mocci G, Pagnini C, Principi MB, Coletta M, Petruzzellis C, Mazzuoli S, Festa S, Mirarnda A, Bezzio C, Fanigliulo L, Rocco G, Pont ED, Spagnuolo R, Savarino EV, Caprioli FA, Fries W, Ceccarelli L, Scaldaferri F, Orlando A, Testa A, Pugliese D, Armuzzi A.

Open source

DOI: 10.1007/s12325-026-03675-4
Published: 2026-06-30
Container: Adv Ther
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s12325-026-03675-4,
  title = {Five-Year Real-World Hard Outcomes of Vedolizumab in Inflammatory Bowel Disease: The IG-IBD LONG-LIVE Study.},
  author = {Privitera G and  Palumbo F and  Macaluso FS and  Laterza L and  Pardi V and  Viola A and  Noviello D and  Barberio B and  Ricci C and  Balestrieri P and  Cappello M and  Maconi G and  Sablich R and  Variola A and  Bennato R and  Pastorelli L and  Grossi L and  Ribaldone DG and  Buda A and  Bossa F and  Di Sario A and  Viscido A and  Neri B and  Mocci G and  Pagnini C and  Principi MB and  Coletta M and  Petruzzellis C and  Mazzuoli S and  Festa S and  Mirarnda A and  Bezzio C and  Fanigliulo L and  Rocco G and  Pont ED and  Spagnuolo R and  Savarino EV and  Caprioli FA and  Fries W and  Ceccarelli L and  Scaldaferri F and  Orlando A and  Testa A and  Pugliese D and  Armuzzi A.},
  year = {2026},
  journal = {Adv Ther},
  doi = {10.1007/s12325-026-03675-4},
  url = {https://doi.org/10.1007/s12325-026-03675-4}
}

RIS

TY  - JOUR
TI  - Five-Year Real-World Hard Outcomes of Vedolizumab in Inflammatory Bowel Disease: The IG-IBD LONG-LIVE Study.
AU  - Privitera G
AU  -  Palumbo F
AU  -  Macaluso FS
AU  -  Laterza L
AU  -  Pardi V
AU  -  Viola A
AU  -  Noviello D
AU  -  Barberio B
AU  -  Ricci C
AU  -  Balestrieri P
AU  -  Cappello M
AU  -  Maconi G
AU  -  Sablich R
AU  -  Variola A
AU  -  Bennato R
AU  -  Pastorelli L
AU  -  Grossi L
AU  -  Ribaldone DG
AU  -  Buda A
AU  -  Bossa F
AU  -  Di Sario A
AU  -  Viscido A
AU  -  Neri B
AU  -  Mocci G
AU  -  Pagnini C
AU  -  Principi MB
AU  -  Coletta M
AU  -  Petruzzellis C
AU  -  Mazzuoli S
AU  -  Festa S
AU  -  Mirarnda A
AU  -  Bezzio C
AU  -  Fanigliulo L
AU  -  Rocco G
AU  -  Pont ED
AU  -  Spagnuolo R
AU  -  Savarino EV
AU  -  Caprioli FA
AU  -  Fries W
AU  -  Ceccarelli L
AU  -  Scaldaferri F
AU  -  Orlando A
AU  -  Testa A
AU  -  Pugliese D
AU  -  Armuzzi A.
PY  - 2026
JO  - Adv Ther
DO  - 10.1007/s12325-026-03675-4
UR  - https://doi.org/10.1007/s12325-026-03675-4
ER  -

APA

G, P., F, P., FS, M., L, L., V, P., A, V., D, N., B, B., C, R., P, B., M, C., G, M., R, S., A, V., R, B., L, P., L, G., DG, R., A, B., F, B., A, D. S., A, V., B, N., G, M., C, P., MB, P., M, C., C, P., S, M., S, F., A, M., C, B., L, F., G, R., ED, P., R, S., EV, S., FA, C., W, F., L, C., F, S., A, O., A, T., D, P., & A., A. (2026). Five-Year Real-World Hard Outcomes of Vedolizumab in Inflammatory Bowel Disease: The IG-IBD LONG-LIVE Study.. Adv Ther. https://doi.org/10.1007/s12325-026-03675-4

Source records

europe-pmc · retrieved 2026-09-26T12:52:55.484Z